Therapeutic RNA interference targeting CKIP-1 with a cross-species sequence to stimulate bone formation

Bone

Volumn 59, Issue , 2014, Pages 76-88

  Guo, Baosheng ^a,b   Zhang, Baoting ^c   Zheng, Lizhen ^c   Tang, Tao ^c   Liu, Jin ^a,b   Wu, Heng ^a,b   Yang, Zhijun ^a,b   Peng, Songlin ^a   He, Xiaojuan ^d   Zhang, Hongqi ^a   Yue, Kevin K M ^a   He, Fuchu ^e   Zhang, Lingqiang ^e   Qin, Ling ^c   Bian, Zhaoxiang ^a,b   Tan, Weihong ^a,f   Liang, Zicai ^b,g   Lu, Aiping ^a,b,d   Zhang, Ge ^a,b  

^a HONG KONG BAPTIST UNIVERSITY   (Hong Kong)

^b Kunshan Industrial Technology Research Institute   (China)

^c CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^d INSTITUTE OF CHINESE MATERIA MEDICA   (China)

^e BEIJING INSTITUTE OF RADIATION MEDICINE   (China)

^f HUNAN UNIVERSITY   (China)

^g PEKING UNIVERSITY   (China)

Author keywords

Bone formation; CKIP 1; Cross species; SiRNA sequences

Indexed keywords

ANABOLIC AGENT; BIOLOGICAL MARKER; BONE MORPHOGENETIC PROTEIN 2; CASEIN KINASE 2 INTERACTING PROTEIN 1; COMPLEMENTARY DNA; LIPOSOME; MESSENGER RNA; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE DENSITY; BONE MASS; BONE MATRIX; BONE MINERALIZATION; BONE STRUCTURE; BONE TURNOVER; CELL DIFFERENTIATION; CONTROLLED STUDY; CORTICAL BONE; CROSS SPECIES SEQUENCE; DRUG ACTIVITY; DRUG TARGETING; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION; GENE LOCATION; GENE SILENCING; GENETIC TRANSCRIPTION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNOGENICITY; IMMUNOSTIMULATION; IN VITRO STUDY; IN VIVO STUDY; LIPOSOMAL DELIVERY; MOUSE; NONHUMAN; OSSIFICATION; OSTEOBLAST; OSTEOLYSIS; OSTEOPOROSIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; PROTEIN TARGETING; PROTEIN URINE LEVEL; RAT; REAL TIME POLYMERASE CHAIN REACTION; RHESUS MONKEY; RNA INTERFERENCE; RNA SEQUENCE; SEQUENCE ANALYSIS; SIGNAL TRANSDUCTION; TRABECULAR BONE; UPREGULATION;

BONE FORMATION; CKIP-1; CROSS-SPECIES; SIRNA SEQUENCES;

ANIMALS; BASE SEQUENCE; BONE MATRIX; BONE MORPHOGENETIC PROTEIN 2; CALCIFICATION, PHYSIOLOGIC; CARRIER PROTEINS; CELL DIFFERENTIATION; COMPUTATIONAL BIOLOGY; FEMALE; FEMUR; GENE KNOCKDOWN TECHNIQUES; HUMANS; IMMUNIZATION; MACACA MULATTA; MICE; OSTEOBLASTS; OSTEOGENESIS; PHENOTYPE; RATS; RNA INTERFERENCE; RNA, MESSENGER; RNA, SMALL INTERFERING; SPECIES SPECIFICITY; UP-REGULATION; X-RAY MICROTOMOGRAPHY;

EID: 84888153117     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2013.11.007     Document Type: Article

References (40)

1. Khosla S., Westendorf J.J., Oursler M.J. Building bone to reverse osteoporosis and repair fractures. J Clin Invest 2008, 118:421-428.
2. Rodan G.A., Martin T.J. Therapeutic approaches to bone diseases. Science 2000, 289:1508-1514.
3. Vegni F.E., Corradini C., Privitera G. Effects of parathyroid hormone and alendronate alone or in combination in osteoporosis. N Engl J Med 2004, 350:189-192. [author reply 189-92].
4. Hodsman A.B., Bauer D.C., Dempster D.W., Dian L., Hanley D.A., Harris S.T., et al. Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use. Endocr Rev 2005, 26:688-703.
5. Lindsay R., Nieves J., Formica C., Henneman E., Woelfert L., Shen V., et al. Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis. Lancet 1997, 350:550-555.
6. Neer R.M., Arnaud C.D., Zanchetta J.R., Prince R., Gaich G.A., Reginster J.Y., et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001, 344:1434-1441.
7. Cosman F., Nieves J., Zion M., Woelfert L., Luckey M., Lindsay R. Daily and cyclic parathyroid hormone in women receiving alendronate. N Engl J Med 2005, 353:566-575.
8. Lu K., Yin X., Weng T., Xi S., Li L., Xing G., et al. Targeting WW domains linker of HECT-type ubiquitin ligase Smurf1 for activation by CKIP-1. Nat Cell Biol 2008, 10:994-1002.
9. Novina C.D., Sharp P.A. The RNAi revolution. Nature 2004, 430:161-164.
10. Guo B.S., Zhang B., Tang T., Liang C., Xie X., Pan X., et al. Increased CKIP-1 protein level negatively associates with decrease in both osteocalcin mRNA and Smad1/5 protein levels in bone specimens from aging men. IOF-ECCEO12 European Congress on Osteoporosis and Osteoarthritis, 21-24 March 2012, Bordeaux, France 2012.
11. Frank-Kamenetsky M., Grefhorst A., Anderson N.N., Racie T.S., Bramlage B., Akinc A., et al. Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates. Proc Natl Acad Sci U S A 2008, 105:11915-11920.
12. Ahn J., Woo H.N., Ko A., Khim M., Kim C., Park N.H., et al. Multispecies-compatible antitumor effects of a cross-species small-interfering RNA against mammalian target of rapamycin. Cell Mol Life Sci 2012, 69:3147-3158.
13. FDA Guidelines for preclinical and clinical evaluation of agents used in the prevention or treatment of postmenopausal osteoporosis 1997, Division of Metabolism and Endocrine Drug Products, USA.
14. WHO Guidelines for preclinical evaluation and clinical trials in osteoporosis 1998, [Geneva].
15. Zhang G., Guo B., Wu H., Tang T., Zhang B.T., Zheng L., et al. A delivery system targeting bone formation surfaces to facilitate RNAi-based anabolic therapy. Nat Med 2012, 18:307-314.
16. Peng S., Zhang G., Zhang B.T., Guo B., He Y., Bakker A.J., et al. The beneficial effect of icaritin on osteoporotic bone is dependent on the treatment initiation timing in adult ovariectomized rats. Bone 2013, 55:230-240.
17. Kretschmer-Kazemi Far R., Sczakiel G. The activity of siRNA in mammalian cells is related to structural target accessibility: a comparison with antisense oligonucleotides. Nucleic Acids Res 2003, 31:4417-4424.
18. Vickers T.A., Koo S., Bennett C.F., Crooke S.T., Dean N.M., Baker B.F. Efficient reduction of target RNAs by small interfering RNA and RNase H-dependent antisense agents. A comparative analysis. J Biol Chem 2003, 278:7108-7118.
19. Yoneyama M., Kikuchi M., Natsukawa T., Shinobu N., Imaizumi T., Miyagishi M., et al. The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses. Nat Immunol 2004, 5:730-737.
20. John M., Constien R., Akinc A., Goldberg M., Moon Y.A., Spranger M., et al. Effective RNAi-mediated gene silencing without interruption of the endogenous microRNA pathway. Nature 2007, 449:745-747.
21. Shin D., Kim S.I., Park M., Kim M. Immunostimulatory properties and antiviral activity of modified HBV-specific siRNAs. Biochem Biophys Res Commun 2007, 364:436-442.
22. Choung S., Kim Y.J., Kim S., Park H.O., Choi Y.C. Chemical modification of siRNAs to improve serum stability without loss of efficacy. Biochem Biophys Res Commun 2006, 342:919-927.
23. Furset G., Sioud M. Design of bifunctional siRNAs: combining immunostimulation and gene-silencing in one single siRNA molecule. Biochem Biophys Res Commun 2007, 352:642-649.
24. Davidson B.L. All in the RNA family. Nat Biotechnol 2006, 24:951-952.
25. Sioud M., Furset G. Molecular basis for the immunostimulatory potency of small interfering RNAs. J Biomed Biotechnol 2006, 2006:23429.
26. Takayama T., Suzuki N., Ikeda K., Shimada T., Suzuki A., Maeno M., et al. Low-intensity pulsed ultrasound stimulates osteogenic differentiation in ROS 17/2.8 cells. Life Sci 2007, 80:965-971.
27. Marie P.J. Transcription factors controlling osteoblastogenesis. Arch Biochem Biophys 2008, 473:98-105.
28. Bancroft G.N., Sikavitsas V.I., van den Dolder J., Sheffield T.L., Ambrose C.G., Jansen J.A., et al. Fluid flow increases mineralized matrix deposition in 3D perfusion culture of marrow stromal osteoblasts in a dose-dependent manner. Proc Natl Acad Sci U S A 2002, 99:12600-12605.
29. Shin H., Temenoff J.S., Bowden G.C., Zygourakis K., Farach-Carson M.C., Yaszemski M.J., et al. Osteogenic differentiation of rat bone marrow stromal cells cultured on Arg-Gly-Asp modified hydrogels without dexamethasone and beta-glycerol phosphate. Biomaterials 2005, 26:3645-3654.
30. Irie K., Zalzal S., Ozawa H., McKee M.D., Nanci A. Morphological and immunocytochemical characterization of primary osteogenic cell cultures derived from fetal rat cranial tissue. Anat Rec 1998, 252:554-567.
31. Garnero P., Vergnaud P., Hoyle N. Evaluation of a fully automated serum assay for total N-terminal propeptide of type I collagen in postmenopausal osteoporosis. Clin Chem 2008, 54:188-196.
32. Diaz-Martin M.A., Traba M.L., De La Piedra C., Guerrero R., Mendez-Davila C., De La Pena E.G. Aminoterminal propeptide of type I collagen and bone alkaline phosphatase in the study of bone metastases associated with prostatic carcinoma. Scand J Clin Lab Invest 1999, 59:125-132.
33. David S., Pitard B., Benoit J.P., Passirani C. Non-viral nanosystems for systemic siRNA delivery. Pharmacol Res 2010, 62:100-114.
34. Yarbrough D.K., Hagerman E., Eckert R., He J., Choi H., Cao N., et al. Specific binding and mineralization of calcified surfaces by small peptides. Calcif Tissue Int 2010, 86:58-66.
35. Posner A.S., Betts F. Synthetic amorphous calcium phosphate and its relation to bone mineral structure. Acc Chem Res 1975, 8:273-281.
36. Soutschek J., Akinc A., Bramlage B., Charisse K., Constien R., Donoghue M., et al. Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 2004, 432:173-178.
37. Zimmermann T.S., Lee A.C., Akinc A., Bramlage B., Bumcrot D., Fedoruk M.N., et al. RNAi-mediated gene silencing in non-human primates. Nature 2006, 441:111-114.
38. Thompson R.N., Phillips J.R., McCauley S.H., Elliott J.R., Moran C.G. Atypical femoral fractures and bisphosphonate treatment: experience in two large United Kingdom teaching hospitals. J Bone Joint Surg Br 2012, 94:385-390.
39. Judge A.D., Sood V., Shaw J.R., Fang D., McClintock K., MacLachlan I. Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA. Nat Biotechnol 2005, 23:457-462.
40. Zhang L., Tang Y., Tie Y., Tian C., Wang J., Dong Y., et al. The PH domain containing protein CKIP-1 binds to IFP35 and Nmi and is involved in cytokine signaling. Cell Signal 2007, 19:932-944.